"Living like an empty gas tank with a leak": Mixed methods study on post-acute sequelae of COVID-19.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
08
2022
accepted:
12
12
2022
entrez:
30
12
2022
pubmed:
31
12
2022
medline:
4
1
2023
Statut:
epublish
Résumé
The burden and presentation of post-acute sequela of SARS-CoV-2 infection (PASC) are a developing major public health concern. To characterize the burden of PASC in community-dwelling individuals and understand the experiences of people living with PASC. This mixed-methods study of COVID-19 positive community-dwelling persons involved surveys and in-depth interviews. Main outcome was self-report of possible PASC symptoms 3 weeks or longer after positive COVID-19 test. In-depth interviews were guided by a semi-structured interview guide with open-ended questions and probes based on emerging literature on PASC and the impact of COVID-19. With a survey response rate of 70%, 442 participants were included in this analysis, mean (SD) age 45.4 (16.2) years, 71% female, 12% Black/African American. Compared to those with no PASC symptoms, persons who reported PASC symptoms were more likely to be older (mean age: 46.5 vs. 42; p = 0.013), female (74.3% vs. 61.2%; p = 0.010), to have pre-existing conditions (49.6% vs. 34%; p = 0.005), and to have been hospitalized for COVID-19 (14.2% vs. 2.9%; p = 0.002). About 30% of the participants experienced severe fatigue; the proportion of persons reporting severe fatigue was 7-fold greater in those with PASC symptoms (Adjusted Prevalence Ratio [aPR] 6.73, 95%CI: 2.80-16.18). Persons with PASC symptoms were more likely to report poor quality of life (16% vs. 5%, p<0.001) and worse mental health functioning (Mean difference: -1.87 95%CI: -2.38, -1.37, p<0.001). Themes from in-depth interviews revealed PASC was experienced as debilitating. In this study, the prevalence of PASC among community-dwelling adults was substantial. Participants reported considerable coping difficulties, restrictions in everyday activities, invisibility of symptoms and experiences, and impediments to getting and receiving PASC care.
Sections du résumé
BACKGROUND
The burden and presentation of post-acute sequela of SARS-CoV-2 infection (PASC) are a developing major public health concern.
OBJECTIVES
To characterize the burden of PASC in community-dwelling individuals and understand the experiences of people living with PASC.
METHODS
This mixed-methods study of COVID-19 positive community-dwelling persons involved surveys and in-depth interviews. Main outcome was self-report of possible PASC symptoms 3 weeks or longer after positive COVID-19 test. In-depth interviews were guided by a semi-structured interview guide with open-ended questions and probes based on emerging literature on PASC and the impact of COVID-19.
RESULTS
With a survey response rate of 70%, 442 participants were included in this analysis, mean (SD) age 45.4 (16.2) years, 71% female, 12% Black/African American. Compared to those with no PASC symptoms, persons who reported PASC symptoms were more likely to be older (mean age: 46.5 vs. 42; p = 0.013), female (74.3% vs. 61.2%; p = 0.010), to have pre-existing conditions (49.6% vs. 34%; p = 0.005), and to have been hospitalized for COVID-19 (14.2% vs. 2.9%; p = 0.002). About 30% of the participants experienced severe fatigue; the proportion of persons reporting severe fatigue was 7-fold greater in those with PASC symptoms (Adjusted Prevalence Ratio [aPR] 6.73, 95%CI: 2.80-16.18). Persons with PASC symptoms were more likely to report poor quality of life (16% vs. 5%, p<0.001) and worse mental health functioning (Mean difference: -1.87 95%CI: -2.38, -1.37, p<0.001). Themes from in-depth interviews revealed PASC was experienced as debilitating.
CONCLUSIONS
In this study, the prevalence of PASC among community-dwelling adults was substantial. Participants reported considerable coping difficulties, restrictions in everyday activities, invisibility of symptoms and experiences, and impediments to getting and receiving PASC care.
Identifiants
pubmed: 36584125
doi: 10.1371/journal.pone.0279684
pii: PONE-D-22-22238
pmc: PMC9803174
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0279684Subventions
Organisme : NIAID NIH HHS
ID : F30 AI165167
Pays : United States
Organisme : NINR NIH HHS
ID : P30 NR018093
Pays : United States
Informations de copyright
Copyright: © 2022 Ogungbe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nat Commun. 2021 Nov 12;12(1):6571
pubmed: 34772922
Cardiovasc Res. 2020 Dec 1;116(14):2177-2184
pubmed: 32750108
Egypt Heart J. 2020 Jul 13;72(1):41
pubmed: 32661796
JAMA Netw Open. 2021 Oct 1;4(10):e2128568
pubmed: 34643720
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Multidiscip Respir Med. 2021 Jan 25;16(1):732
pubmed: 33623700
Nat Med. 2022 Mar;28(3):583-590
pubmed: 35132265
Eur Respir J. 2021 Aug 26;58(2):
pubmed: 33926969
JACC Basic Transl Sci. 2021 Sep-Oct;6(9):796-811
pubmed: 34541421
Med Teach. 2020 Aug;42(8):846-854
pubmed: 32356468
J Infect Dis. 2021 Dec 1;224(11):1839-1848
pubmed: 34677601
Qual Life Res. 2009 Sep;18(7):873-80
pubmed: 19543809
Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):98-105
pubmed: 20123676
J Gen Intern Med. 2021 Oct;36(10):3179-3187
pubmed: 33886027
J Am Coll Cardiol. 2022 May 3;79(17):1717-1756
pubmed: 35307156
Oncol Nurs Forum. 2014 Sep;41(5):545-7
pubmed: 25158659
J Appl Physiol (1985). 2021 May 1;130(5):1470-1478
pubmed: 33764166
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Int J Cardiol Heart Vasc. 2022 Jun;40:100950
pubmed: 35005211
Glob Heart. 2020 Sep 22;15(1):64
pubmed: 33150129
Pathogens. 2021 Jun 17;10(6):
pubmed: 34204243
Curr Epidemiol Rep. 2021;8(1):1-8
pubmed: 33425654
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
J Clin Transl Sci. 2021 Jul 14;5(1):e152
pubmed: 34462668
Health Qual Life Outcomes. 2003 Dec 16;1:79
pubmed: 14678568
Health Qual Life Outcomes. 2021 Sep 27;19(1):226
pubmed: 34579721
JAMA Netw Open. 2021 Feb 1;4(2):e210830
pubmed: 33606031
Front Rehabil Sci. 2021 Aug 31;2:710410
pubmed: 36188869